Gastroesophageal Adenocarcinoma
FDA grants priority review to therapy for relapsed leukemia, lymphoma
The FDA announced several regulatory actions.
Pembrolizumab regimen extends OS in metastatic gastric, gastroesophageal junction cancers
The addition of pembrolizumab to chemotherapy improved OS among certain patients with gastric or gastroesophageal junction cancers, according to the agent’s manufacturer.
FDA grants orphan drug designation to natural killer cell therapy for GI cancers
The FDA granted orphan drug designation to CYNK-101, an investigational natural killer cell-based therapy for treatment of advanced HER2/neu-positive gastric or gastroesophageal junction adenocarcinoma.
Nivolumab plus chemotherapy shows durable efficacy in gastric, esophageal cancers
Nivolumab plus chemotherapy continued to confer clinically meaningful improvement in OS and PFS as first-line therapy for advanced gastric and esophageal cancers, according to a study presented at Gastrointestinal Cancers Symposium.
FDA grants fast track designation to natural killer cell therapy for GI cancers
The FDA granted fast track designation to CYNK-101, a natural killer cell-based therapy for treatment of advanced HER2/neu-positive gastric or gastroesophageal junction adenocarcinoma.
Addition of bermarituzumab to mFOLFOX treatment outperforms placebo
FDA grants breakthrough therapy designation to bemarituzumab for gastric cancers
The FDA granted breakthrough therapy designation to bemarituzumab for use with chemotherapy as first-line treatment of certain patients with gastrointestinal cancers, according to the agent’s manufacturer.